Iovance Biotherapeutics Inc

Latest Results (13.04.2026):

Iovance Biotherapeutics, Inc. reported third quarter 2025 results showing continued commercial traction for Amtagvi with product revenue of about $67.5 million (≈$68M), a 13% increase sequentially, improved gross margin of 43%, and a net loss of $91.3 million (net loss per share $0.25). The company ended the quarter with roughly $307 million in cash, investments, and restricted cash and reaffirmed full‑year 2025 revenue guidance of $250–$300 million.

Revenue and Growth

Q3 2025 product revenue was $67.455M (U.S. Amtagvi ≈ $58M; global Proleukin ≈ $10M), a 13% increase over the prior quarter; total nine‑month 2025 product revenue was $176.7M.

Gross Margin and Cost of Sales

Gross margin improved to 43% in Q3 2025 with cost of sales of $38.5M, reflecting better execution and initial benefits from cost‑optimization initiatives.

Profitability and Operating Results

Loss from operations in Q3 2025 was $94.9M; net loss for the quarter was $91.3M. Net loss per share (basic and diluted) was $0.25. Q3 included $5.143M of restructuring charges.

Operating Expenses and Non‑Cash Items

Q3 2025 R&D expense was $75.2M and SG&A was $34.6M. Total stock‑based compensation included in costs and expenses for the quarter was $11.9M (non‑cash).

Cash Position and Runway

Cash, cash equivalents, investments, and restricted cash totaled approximately $307M as of September 30, 2025; management expects the current cash position, together with expense reductions, to fund operations into Q2 2027.

Guidance and Margin Improvement Plans

Full‑year 2025 revenue guidance was reaffirmed at $250–$300M. Management plans to centralize manufacturing at the Iovance Cell Therapy Center in early 2026 to reduce external manufacturing expenses and further improve gross margins.

Commercial Execution Metrics

More than 80 U.S. authorized treatment centers are activated across nearly 40 states (≈95% of patients within a two‑hour drive). Manufacturing turnaround time improved to an average of 32 days from inbound to return shipment, supporting increasing Amtagvi demand.